New Phase Appoints U.S. Cancer Expert Prof. Jeff Geschwind to Scientific Advisory Board

New Phase, a company dedicated to advancing oncology treatments, has appointed Professor Jeff Geschwind to its Scientific Advisory Board. Professor Geschwind is a recognized expert in cancer care based in the United States.

The appointment is intended to bolster New Phase's research and development efforts in oncology. Professor Geschwind brings extensive experience and expertise in the field of cancer treatment. Specific details regarding his advisory responsibilities have not yet been disclosed by the company.

New Phase specializes in early-stage research and clinical trials for novel cancer therapies. The company aims to bring new treatment options to patients. The addition of Professor Geschwind to its advisory board aligns with New Phase's strategy to build a robust scientific foundation for its operations.

Professor Geschwind has held positions at several academic and clinical research institutions in the U.S. His work has primarily focused on the development of new cancer drugs and the optimization of treatment protocols.